SPRO:NASDAQSpero Therapeutics, Inc. Analysis

The moving-average structure behind Spero Therapeutics, Inc. is bearish at $1.22, with short-term averages lagging the long-term ones. Across the trailing 30 sessions it lost 15.3%. RSI sits at 37.7, which reads as approaching oversold, and MACD momentum is bullish. Price has been bracketed by support at $1.15 and resistance at $1.30.
Valuation screens as undervalued: a P/E of 8.7 sits below the sector average of 30.4. Consensus targets land 227.9% above where the shares trade now.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 50.5%, a beta of 1.47 and a maximum drawdown of 61.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons diverge: hold near-term but buy on a long view, at 5/10 conviction over the longer horizon.